SAHPRA Biosimilars Approval: Pathway Analysis & Impact on Affordable Medicines

Key Takeaways

South Africa's regulatory authority for biological medicines, the South African Health Products Regulatory Authority (SAHPRA), has updated its biosimilars approval pathway in 2025 to incorporate international best practices and enhance access to affordable biological therapies. The updated framework, which supersedes guidance initially issued in 2014, establishes a rigorous yet harmonized evaluation process for biosimilar applications, requiring applicants to demonstrate comprehensive comparability to a South African-registered reference product through analytical, non-clinical, and clinical studies. Why it matters: This alignment with global regulatory standards positions South Africa as a more attractive market for biosimilar manufacturers while strengthening the quality and safety standards that protect patients in the region.

Drug Overview

Biosimilars are biological medicinal products that demonstrate high similarity to an already-approved reference biologic in terms of quality, safety, and efficacy. Unlike generic small-molecule drugs, biosimilars are complex molecules derived from living cells and require extensive comparability assessment rather than simple bioequivalence studies. The biosimilar class encompasses a broad range of therapeutic agents, including monoclonal antibodies, fusion proteins, cytokines, and growth factors used across multiple therapeutic areas such as oncology, immunology, endocrinology, and hematology.

SAHPRA's regulatory framework applies to all biosimilar applications seeking market authorization in South Africa, regardless of the specific biologic class or therapeutic indication. The pathway is designed to ensure that approved biosimilars meet the same stringent quality and safety standards expected of innovator biologics while facilitating patient access to more affordable treatment options.

SAHPRA's Updated Biosimilar Approval Requirements

SAHPRA's biosimilar approval pathway mandates that applicants conduct a comprehensive comparability exercise to demonstrate that their proposed biosimilar is similar to a South African-registered reference product. This requirement encompasses three distinct components:

The primary evaluation of biosimilar applications is conducted by SAHPRA's Biological Medicines Committee, a specialized body within the regulatory authority responsible for assessing the quality, safety, and efficacy of biological products. This committee comprises experts in biologics evaluation, clinical pharmacology, and related disciplines.

The 2025 update to SAHPRA's biosimilar guidance incorporates lessons learned from the original 2014 framework and reflects alignment with international best practices established by regulatory authorities including the European Medicines Agency (EMA) and the World Health Organization (WHO). This harmonization reduces uncertainty for manufacturers navigating multiple regulatory jurisdictions and strengthens the scientific rigor of the approval process.

Regulatory Context

SAHPRA's biosimilar approval pathway was initially established in 2014 as South Africa sought to create a transparent, science-based framework for evaluating biosimilar applications. The original guidance reflected international consensus on the comparability approach but was refined over the subsequent decade as regulatory experience accumulated globally and scientific understanding of biosimilar assessment evolved.

The 2025 update represents a formal revision of this guidance, incorporating international best practices and ensuring that SAHPRA's requirements remain aligned with those of other major regulatory authorities. The updated framework applies to all new biosimilar applications submitted after the guidance publication date, though SAHPRA may provide transitional guidance for applications already in progress at the time of update.

No specific submission timelines, conditional approval pathways, or accelerated review designations are currently detailed in the publicly available guidance. However, the structured comparability approach is designed to provide applicants with a predictable evaluation timeline and clear expectations regarding data requirements.

Market Impact and Access to Affordable Medicines

The updated SAHPRA biosimilar pathway carries significant implications for pharmaceutical market dynamics and patient access in South Africa. By establishing a rigorous yet predictable approval process, the framework is expected to facilitate market entry for biosimilar manufacturers, compared with less harmonized regulatory environments where biosimilar applications face prolonged uncertainty or unclear requirements.

Increased biosimilar availability is anticipated to enhance competition in the biological medicines market, potentially reducing prices and improving affordability of treatments for chronic conditions such as rheumatoid arthritis, inflammatory bowel disease, cancer, and diabetes. This is particularly important in South Africa, where healthcare budgets are constrained and patient access to expensive biological therapies remains limited.

The pathway encourages both local South African biosimilar manufacturers and international companies to invest in biosimilar development for the South African market. Local manufacturers, in particular, may leverage the comparability framework to develop biosimilars of commonly used reference products, supporting domestic pharmaceutical capacity and creating employment opportunities.

What to watch next: Regulatory harmonization efforts across the African continent, including potential collaboration between SAHPRA and the African Medicines Agency, could further streamline biosimilar approvals across multiple African markets, creating a larger addressable market for manufacturers and expanded treatment options for patients throughout the region.

Future Outlook and Strategic Considerations

The biosimilar market in South Africa and the broader Middle East and Africa (MEA) region is expected to expand significantly as the updated SAHPRA pathway facilitates increased biosimilar approvals. Manufacturers that align their development and regulatory strategies with SAHPRA's updated requirements—particularly regarding comparability study design and reference product selection—are positioned to achieve more efficient regulatory approval timelines and market entry.

Strategic manufacturers should anticipate that SAHPRA's framework will continue to evolve as global regulatory standards advance. Staying abreast of updates from the EMA, WHO, and other major regulatory authorities will be essential for manufacturers planning multi-jurisdictional biosimilar launches that include South Africa.

Potential challenges for biosimilar manufacturers include ensuring access to appropriate South African-registered reference products for comparability studies and designing clinical trials that adequately represent the South African patient population. Additionally, manufacturers must navigate intellectual property considerations and ensure that their biosimilar development does not infringe on existing patents or regulatory exclusivity periods applicable to reference products.

Opportunities exist for SAHPRA to further harmonize its biosimilar pathway with other African regulatory bodies and the African Medicines Agency, potentially creating a unified approval framework that facilitates regional biosimilar distribution and reduces development costs for manufacturers serving multiple African markets.

Frequently Asked Questions

References

1. South African Health Products Regulatory Authority (SAHPRA). Biosimilar Approval Pathway Guidance (2025 Update). [Source 1: SAHPRA biosimilar regulatory guidance incorporating analytical, non-clinical, and clinical comparability requirements; Biological Medicines Committee evaluation role; 2014 original framework and 2025 international alignment.]